Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PLA2G4B | P0C869 | 6/20 | 0.55 |
| ▸ | PLK1 | P53350 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 4/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3555944 | 0.99 | TP53 (0.59) | L3MBTL1POLBATMTP53TSHR | |
| SCHEMBL3559669 | 0.99 | TP53 (0.59) | L3MBTL1POLBATMTP53TSHR | |
| SCHEMBL3559044 | 0.97 | POLB (0.62) | L3MBTL1POLBATMTP53TSHR | |
| SCHEMBL3557542 | 0.92 | GAA (0.56) | L3MBTL1POLBATMTP53TSHR | |
| SCHEMBL11644679 | 0.87 | GAA (0.64) | L3MBTL1POLBATMTSHRGAA | |
| SCHEMBL3557480 | 0.86 | CYP2C19 (0.62) | L3MBTL1POLBGAAPKMCYP2C19 | |
| SCHEMBL3555523 | 0.82 | TSHR (0.56) | L3MBTL1TSHRGAAPKM | |
| SCHEMBL3556661 | 0.82 | L3MBTL1 (0.65) | L3MBTL1POLBTSHRPKM | |
| SCHEMBL8158170 | 0.82 | CYP2C19 (0.64) | L3MBTL1POLBATMGAACYP2C19 | |
| SCHEMBL3556618 | 0.81 | POLB (0.62) | L3MBTL1POLBTSHRRARBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | L3MBTL1 2080/4885POLB 3962/4885ATM 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.